The pharma stock market was built on the framework and understanding that, as medical experts discover new diseases, companies in the sector are responsible for creating innovative treatment options to combat these ailments. It is for this reason, among many others, that there is an high demand for qualitative healthcare, on both a domestic and global scale. It would serve companies in the healthcare industry well to do everything in their power to champion products meant to help patients feel as healthy as possible, resulting in the creation of potential investor opportunities. Premier Health Group (OTC: PHGRF) (CSE: PHGI), Teligent Inc (NASDAQ: TLGT), Inovio Pharmaceuticals Inc (NASDAQ: INO), and Aurora Cannabis Inc (NYSE: ACB, TSX: ACB) are 4 pharma stocks to keep tabs on as the industry moves toward the future.
Premier Health Group (OTC: PHGRF) (CSE: PHGI), a company that you may not have heard of, but could potentially benefit from looking into, recognizes the importance of investing in the future of the pharmaceutical industry, and amid this understanding, has made key acquisitions and investments over the last few months to assure the best quality of products/care options for their patients.
Premier Health Group (OTC: PHGRF) (CSE: PHGI) today announced it is moving forward with a binding Letter of Intent (“LOI”) to acquire two Metro Vancouver-based pharmacies. The pharmacies were cash flow positive and had combined annual revenue of over $6 million for the fiscal year ended May 31, 2018. Premier Health expects the acquisition to close in or about Q2 2019.
Dr. Essam Hamza, CEO of Premier Health Group (OTC: PHGRF) (CSE: PHGI), said, “We are very excited about this opportunity to acquire two well-run and profitable pharmacies. As part of our patient-centric model, fill and fulfillment is a major component of our telemedicine app. We are also pleased to have the pharmacies’ key management team, with over 20 years’ experience managing pharmacies, come on board to continue running the operations. We look forward to working together to improve fulfillment for our rapidly growing patient base. In addition, with one of the pharmacies occupying a space of over 6000 square feet, we have a potential opportunity for a brand-new medical clinic expansion.”
For More Information On Premier Health Group, Click Here
Teligent Inc (TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Ointment USP, 0.05%. This is Teligent’s first approval of 2019, and its thirty-third approval from its internally-developed pipeline of topical generic pharmaceutical medicines.
In a press release regarding the announcement, Jason Grenfell-Gardner, President and CEO of Teligent, said, “The first approval of 2019 is an important one for Teligent as we continue on our growth trajectory. We now have thirty-eight topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”